LONDON, May 16, 2017 /PRNewswire/ --
Next-Generation Sequencing (NGS), Microarray, Circulating Tumour Cells (CTCs) Analysis, In Situ Hybridization (ISH), Advanced PCR Techniques
The next-generation cancer diagnostics market is expected to grow at a CAGR of 16.5% in the first half of the forecast period and CAGR of 19.1% in the second half of the forecast period. The market is estimated at $1.9bn in 2016 and $4.1bn in 2021, says Visiongain.
While the number of new cancer cases is expected to reach 24 million by 2035, the cost savings that could be achieved with early diagnosis will be the main driver for the market. Advances in molecular biology will also help expand the cancer diagnostics test menu.
Companion cancer diagnostics can be costly but we expect them to be increasingly adopted, particularly when choosing expensive cancer therapies. Laboratory automation, standardised commercial cancer tests and affordable benchtop instruments will continue to reduce the costs of molecular testing.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 166-page report you will receive 87 charts - all unavailable elsewhere.
The 166-page report provides clear detailed insight into the next-generation cancer diagnostics market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
• Forecasts and analysis of the next-generation cancer diagnostics market from 2017 to 2027.
• 5 next-generation cancer diagnostics submarkets forecast and analysis from 2017 to 2027:
- Advanced PCR Techniques
- In Situ Hybridization (ISH)
- Circulating Tumour Cells (CTCs) Analysis
- Next-Generation Sequencing (NGS)
• Revenue forecasts for 8 leading national or regional next-generation cancer diagnostics market from 2017 to 2027:
- Rest of the World
• Assessment of selected leading companies marketing next-generation cancer diagnostics, examining recent performance and outlooks:
- Roche Diagnostics
- Abbott Laboratories
- Thermo Fisher Scientific
- Agilent Technologies
- Myriad Genetics
• SWOT analysis of the next-generation cancer diagnostics market, and discusses some current trends.
Visiongain's study is intended for anyone requiring commercial analyses for the next-generation cancer diagnostics market. You find data, trends and predictions.
Buy our report today Next-Generation Cancer Diagnostics Market Forecast 2017-2027: Next-Generation Sequencing (NGS), Microarray, Circulating Tumour Cells (CTCs) Analysis, In Situ Hybridization (ISH), Advanced PCR Techniques.
To request a report overview of this report please email Sara Peerun at email@example.com or call Tel: +44-(0)-20-7336-6100
The companies mentioned are:
454 Life Sciences
Advanced Cell Diagnostics
Advanced Liquid Logic
ARCH Venture Partners
Iris Molecular Diagnostics
Thermo Fisher Scientific
Ventana Medical Systems
List of Organizations Mentioned in the Report
Actionable Genome Consortium
Arizona State University
Carnegie Mellon University
First Oncology Research and Advisory Center
MGH Cancer Center
Massachusetts Institute of Technology
National Cancer Center
Pennsylvania State University
To see a report overview please email Sara Peerun on firstname.lastname@example.org
SOURCE Visiongain Ltd